source
- Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorderWith a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could supp…
- Regulators Share Guidance for Effective Sponsor MeetingsRegulators from the U.S. FDA, the U.K. MHRA and other European agencies met to outline best practices for sponsor‑regulator interactions. They highlighted that transparency, open collaboration, at…